简介:目的探讨玻璃体腔注射雷珠单抗辅助23G玻璃体切割治疗增殖期糖尿病视网膜病变的优质护理。方法通过对28例28眼采用玻璃体腔注射雷珠单抗辅助玻璃体切割治疗糖尿病患者并发视网膜增殖期病变存在的主要护理问题,针对患者治疗各阶段,责任护士提供全程、连续、系统的优质护理服务,加强护患沟通,提高护理质量,缩短手术时间,减少并发症的发生。结果24眼一次性手术复位成功(85.7%)术后三个月取出硅油,其中有4例伴有晶状体混浊的同时行晶状体超声乳化联合人工晶体植入术;4例硅油填充下仍然存在下方局限性视网膜增殖,术后三个月取出硅油再次切割增殖膜然后注入C3F8气体填充,随访至气体完全吸收,视网膜复位。结论对玻璃体腔注射雷珠单抗辅助23G玻璃体切割治疗增殖期糖尿病视网膜病变的患者提供优质护理,可缩短手术时间,减少并发症的发生,提高病人及家属的满意度,提升患者的康复效果,是手术取得成功的关键因素。
简介:·Thisisacasepresentationofaverybizarreopenglobetraumawithanteriorsegmentforeignbody-fishinghookstuckinthecorneaandiris.Complicationsduetothiskindofeyetraumamightbeveryhazardousandwithseriousimpactonvisualfunction.Wearerepresentingourapproachandexperienceofthreestepmanagementofthiskindofeyeinjury:first-extracttheforeignbody,closeandreconstructtheeyeball,second-fightinflammation,andthird-restorethevisualfunctionbycataractsurgery.·
简介:AIM:Tocomparetheeffectoftopicallyadministeredandsubconjunctivallyinjectedbevacizumabonexperimentalcornealneovascularizationinratsfortwoweeksaftertreatment.METHODS:Twenty-eightSprague-Dawleyratsweredividedintofourgroupsof7animals.Eachcornealcenterofrighteyewascauterizedwithsilver/potassiumnitratefor8s.Aftercornealburning,bevacizumab(12.5mg/mL)wastopicallyadministeredthreetimesperday(TBgroup)fortwoweeksorsubconjunctivallyinjectedondays2and4aftercauterization(0.02mL;SBgroup).Asnegativecontrols,ratsreceived0.9%salinetopicallythreetimesperday(TSgroup)orsubconjunctivallyondays2and4(0.02mL;SSgroup).Digitalphotographsofthecorneaweretaken1and2weeksaftertreatmentandanalyzedtodeterminetheareaofcorneacoveredbyneovascularizationasthepercentageofcornealneovascularization.RESULTS:Oneweekaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBandSBgroupsthanintheTSandSSgroups(allP<0.05).Twoweeksaftertreatment,thepercentageofcornealneovascularizationwassignificantlylowerintheTBgroupthanintheTSgroup(P<0.05).Inallgroups,thepercentageofneovascularizationwasdecreasingastimepassed(allP<0.05)CONCLUSION:Topicallyadministeredbevacizumabhaslongerstandinganti-angiogeniceffectthansubconjunctivallyinjectedbevacizumabincornealneovascularizationfollowingchemicalinjuryinrats.